8 Best Small-Cap Growth Stocks to Buy According to Analysts
During the third quarter of 2024, small-cap stocks represented by the Russell 2000 Index made a strong comeback after a somewhat disappointing second quarter.
Celldex Therapeutics Inc. (CLDX)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Kynam Capital Derrick Tang | 3,458,609 | $117,558,120 | +3% | 9.01% |
| 2. | Polar Capital Brian Ashford-Russell And Tim Woolley | 2,720,877 | $92,482,609 | -12% | 0.44% |
| 3. | Woodline Partners Michael Rockefeller And Karl Kroeker | 2,341,121 | $79,574,703 | +209% | 0.67% |
| 4. | Commodore Capital Egen Atkinson And Michael Kramarz | 1,618,937 | $55,027,669 | +14% | 3.43% |
| 5. | Point72 Asset Management Steve Cohen | 1,568,708 | $53,320,399 | -20% | 0.13% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $26.82 | 11,500 | 40,284 | 2024-11-11 | Filing | ||
| $46.28 | 430 | Officer | 430 | 2021-08-11 | Filing | |
| $4.73 | 2,115 | Officer | 2,115 | 2020-06-11 | Filing | |
| $4.83 | 1,050 | Officer | 1,367 | 2020-06-10 | Filing | |
| $3.01 | 1,000 | Officer | 1,000 | 2020-06-09 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $35.42 | 17,172 | 28,125 | 2024-06-14 | Filing | ||
| $34.87 | 30,000 | 9,074 | 2024-06-14 | Filing | ||
| $35.06 | 15,000 | 9,074 | 2024-06-07 | Filing | ||
| $35.26 | 45,000 | 2,115 | 2024-06-07 | Filing | ||
| $33.65 | 58,369 | 13,383 | 2024-06-03 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 7,050,409 | $279,619,221 | 0.02% | |
| 2. | 6,476,561 | $256,860,411 | 0.04% | |
| 3. | 3,675,692 | $145,777,945 | 0% | |
| 4. | 3,630,013 | $143,966,316 | 2.34% | |
| 5. | 3,463,201 | $137,350,552 | 2.14% |
News See All
10 Most Promising Small-Cap Stocks According to Hedge Funds
Small-cap stocks are offering a myriad of opportunities to investors and are expected to go higher.
10 Worst Cancer Stocks To Buy Now According to Short Sellers
Cancer is the second leading cause of death globally, just behind cardiovascular disease, making oncology one of the largest sectors in the life sciences.
Top 10 Biotech Stocks to Buy According to Jeremy Green's Redmile Group
In this article, we will discuss the top 10 biotech stocks to buy according to Jeremy Green's Redmile Group.
Hedge Funds Are Crazy About Celldex Therapeutics, Inc. (CLDX)
In this article we are going to use hedge fund sentiment as a tool and determine whether Celldex Therapeutics, Inc. (NASDAQ:CLDX) is a good investment right now.
Should I Avoid Celldex Therapeutics, Inc. (CLDX)?
While the market driven by short-term sentiment influenced by the accommodative interest rate environment in the US, virus news and stimulus spending, many smart money investors are starting to get cautious...
5 Stocks to Buy According to Neil Shahrestani's Ikarian Capital
In this article, we will discuss the 10 stocks to buy according to Neil Shahrestani's Ikarian Capital.
Where Do Hedge Funds Stand On Celldex Therapeutics, Inc. (CLDX)?
Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities...
Is CLDX Stock A Buy or Sell?
In this article we will take a look at whether hedge funds think Celldex Therapeutics, Inc. (NASDAQ:CLDX) is a good investment right now.